{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-109637","form_type":"8-K/A","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2025-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.182953+00:00","generated_at":"2026-05-17T12:01:20.036740+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"HCW Biologics Q2 net loss narrows to $1.9M; revenue drops 99%, going concern noted","bullets":["Q2 2025 revenue $6,550 vs $618,854 in Q2 2024 after suspending Wugen license.","Net loss improved to $1.9M from $15.3M YoY due to $10.4M arbitration legal fees in prior year.","Closed $5.0M equity offering on May 15, 2025; extinguished $7.7M debt via restructuring.","Substantial doubt about going concern without additional funding within 12 months.","Phase 1 trial for HCW9302 in alopecia areata on track for Q3 2025 launch."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-109637","json":"https://secwatch.observer/filing/0000950170-25-109637.json","markdown":"https://secwatch.observer/filing/0000950170-25-109637.md","text":"https://secwatch.observer/filing/0000950170-25-109637.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000095017025109637/0000950170-25-109637-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000095017025109637/hcwb-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:01:20.036740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}